Know Cancer

or
forgot password

A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Docetaxel (TAXOTERE)


Phase 1
N/A
N/A
Not Enrolling
Both
Solid Tumor Cancer

Thank you

Trial Information

A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Docetaxel (TAXOTERE)


Inclusion Criteria:



- Advanced solid tumors.

- Able to swallow oral medication.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and Tolerability

Principal Investigator

GSK Clinical Trials, MD

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

United States: Food and Drug Administration

Study ID:

EGF10021

NCT ID:

NCT00148902

Start Date:

April 2003

Completion Date:

Related Keywords:

  • Solid Tumor Cancer
  • tumor

Name

Location

GSK Investigational SiteGermantown, Tennessee  38138